Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi recently updated its clinical study on SAR443579, a first-in-human trial aimed at evaluating the safety and efficacy of this drug in treating relapsed or refractory acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), high-risk myelodysplasia (HR-MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The study’s official title is ‘An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants.’ The study holds significant potential for advancing treatment options for these challenging hematological malignancies.
The intervention being tested is SAR443579, an experimental drug administered intravenously. It is designed to assess its anti-leukemic activity, safety, pharmacokinetics, and pharmacodynamics in affected patients.
The study is interventional in nature, utilizing a single-group assignment model without masking, focusing primarily on treatment. It involves dose escalation and expansion phases to determine the optimal dosage and schedule for SAR443579.
The study commenced on December 8, 2021, but was terminated as of the last update on August 4, 2025. These dates are crucial for understanding the study’s timeline and its progression through various phases.
The termination of this study may impact Sanofi’s stock performance and investor sentiment, as it suggests potential challenges with the drug’s development. This could influence market dynamics, especially in comparison to competitors actively developing treatments for similar conditions.
The study is currently terminated, and further details can be accessed on the ClinicalTrials portal.